Web Research

What the Internet Reveals

The Bottom Line from the Web

Two events in the last 90 days reframe the Yatsen story: a ¥860M (US$120M) related-party convertible note placement announced March 11, 2026 — funded by founder/CEO Jinfeng Huang and Trustar Capital at a $4.63 conversion price — and a first-ever full-year non-GAAP profit (¥8.4M) for FY2025 disclosed March 2, 2026 alongside +26.7% revenue growth. The market read the combination as bearish on net: shares fell ~9% on the earnings print and another ~10% on the convertible deal, and YSG is now down 97% since its 2020 IPO, trading near the bottom of its 52-week range despite analyst median targets at $5.80 (implied +76%).

What Matters Most

1. Founder + Trustar fund a ¥860M convertible — bullish signal or shareholder dilution?

On **March 11, 2026**, Yatsen agreed to sell ~US$120M (≈¥860M) of RMB-denominated convertible senior notes plus warrants in two equal tranches to an investment vehicle affiliated with Trustar Capital, with founder/CEO Jinfeng Huang personally subscribing. Notes carry a **1.5% coupon**, convert after 364 days at **$4.63** (a 20% premium to the pre-deal price), and warrants equal one-tenth of conversion shares. Stock dropped ~10.5% on the news. Source: [stocktitan.net/news/YSG](https://www.stocktitan.net/news/YSG/), [yahoo finance](https://finance.yahoo.com/markets/stocks/articles/yatsen-holding-ysg-one-top-045145500.html).

The deal is dual-edged. Bullish read: the founder is putting fresh capital in personally — proceeds fund R&D, supply-chain integration, overseas expansion and M&A. Bearish read: this is a related-party financing where the controlling shareholder (Huang already owns ~35%) gets cheap convertible terms (1.5% coupon, modest 20% conversion premium) that minority shareholders cannot match, and the warrant kicker compounds dilution. With ¥1.05B cash on the balance sheet at year-end, the strategic necessity of the raise is also questionable.

2. FY2025: first non-GAAP profit since IPO, but Q4 quality deteriorated

FY2025 net revenue **¥4.30B (+26.7% YoY)**; gross margin **78.2%** (+110bps); net loss narrowed to **¥92.4M from ¥710.2M**; **non-GAAP net income ¥8.4M** vs prior-year non-GAAP loss. Source: [yahoo finance Q4 2025 highlights](https://finance.yahoo.com/news/yatsen-holding-ltd-ysg-q4-190038111.html), [stocktitan.net](https://www.stocktitan.net/news/YSG/).

The FY headline is genuinely a turnaround — but Q4 alone shows cracks. Q4 net revenue rose 20.1% to ¥1.38B, yet Q4 non-GAAP net income fell to ¥41.2M from ¥107M the prior year, selling & marketing rose to 64.8% of revenue on higher traffic acquisition costs during shopping festivals, and operating cash flow used ¥69.4M in Q4 (¥94.7M used for FY). Color cosmetics revenue declined 9.1% YoY in Q4, validating the bearish thesis that the legacy Perfect Diary engine is still shrinking. Stock fell 8.99% on the print.

3. Stock down 97% since IPO — and 33% in the last year

Yatsen IPO'd at $10.50/ADS on November 19, 2020 (raising US$616.9M with Morgan Stanley, Goldman, CICC as bookrunners). At ~$2.85 today, the stock has lost roughly **97% from IPO and ~98% from its 2021 peak**. Market cap has collapsed to ~$268M from a one-time peak of ~$25B. 1-year return: −33%; 5-year: −95%. Source: [fool.com YSG quote](https://www.fool.com/quote/nyse/ysg/), [financialmodelingprep](https://site.financialmodelingprep.com/market-news/yatsen-holding-strategic-transformation-financial-challenges).

4. Securities class action lawsuit alleges IPO-era misrepresentations

**Levi & Korsinsky** filed a securities class action covering ADS purchases between Nov 19, 2020 (IPO) and Mar 10, 2022. Allegation: Yatsen misled investors that Perfect Diary and Little Ondine were thriving while sales were already declining. **Glancy Prongay & Murray LLP** also opened an investigation in late 2022. Trigger events: (a) Aug 26, 2021 disclosure that Perfect Diary was "deteriorating" — stock fell 17.6% to $4.81; (b) Nov 17, 2021 Q3 results — stock fell 17.9% to $2.70; (c) Mar 10, 2022 FY2021 results showing −22.1% revenue and −17.2% gross profit. Source: [zlk.com class action](https://zlk.com/cases/yatsen-holding-limited-class-action-lawsuit-ysg), [businesswire](https://www.businesswire.com/news/home/20220926005794/en/).

The litigation centers on the IPO disclosures. No public update in the last 90 days, but the class action remains an unresolved overhang.

5. Insider Form 144 sale by company executive (June 2025)

A Yatsen Holding insider filed Form 144 on **June 26, 2025** notifying intent to sell **100,000 ADSs** (representing 2 million Class A ordinary shares) for an aggregate market value of **$966,000** — through Tiger Brokers, NYSE, sale date June 27, 2025. The shares were acquired Feb 1, 2024 via the company's Share Incentive Plan in a cashless transaction. Source: [stocktitan.net SEC filings](https://www.stocktitan.net/sec-filings/YSG/144-yatsen-holding-limited-american-sec-filing-fe5632a0032e.html).

The Form 144 doesn't name the filer publicly but signals an executive monetizing equity comp at a depressed price. Note that the insider transaction percent shown on Finviz is 0% — small relative to total shares.

6. Analyst coverage is thin and divided

Median 1-year price target: **$5.80** (≈+76% upside vs $2.85), per Insider Monkey/yahoo. **Morningstar Quantitative fair value: $2.57** (stock trades at 11% premium per their model). Reuters lists only **1 active sell-side analyst** with a "Hold" recommendation. Earlier Simply Wall St note (June 2025) cited **3 American Personal Products analysts** projecting CN¥34M net profit for 2025 — Yatsen actually printed CN¥−92.4M GAAP / CN¥+8.4M non-GAAP, broadly in line on the non-GAAP basis. Source: [morningstar.com/stocks/xnys/ysg](https://www.morningstar.com/stocks/xnys/ysg/quote), [yahoo finance](https://finance.yahoo.com/news/yatsen-holding-limited-nyse-ysg-132059064.html).

The dispersion ($2.57 fair value vs $5.80 target) reflects deep uncertainty about whether the skincare pivot is durable.

7. Q1 2026 guidance: +15% to +30% revenue growth

Management guided Q1 2026 net revenues to ¥958.6M–¥1.08B — a 15% to 30% YoY range. The midpoint (~22%) is a deceleration from FY2025's +26.7% but consistent with "growth at scale" framing. Source: stocktitan.net/news/YSG.

8. Skincare is now the majority of revenue — pivot is real

Skincare brands (Galénic, Dr.WU mainland China, Eve Lom, EANTiM) reached 53.0% of FY2025 revenue with +63.5% YoY growth, while Q4 skincare alone was 61.1% of revenue with +51.9% growth. Color cosmetics (Perfect Diary, Little Ondine, Pink Bear) declined 9.1% YoY in Q4. The portfolio mix shift is the central driver of the gross margin lift to 78.2%. Source: yahoo finance Q4 2025, yahoo finance Q2 2025.

9. Cash runway is workable but not abundant

Cash, restricted cash and short-term investments at Dec 31, 2025: ¥1.05B. The convertible adds another ~¥860M (≈¥430M in tranche 1 around March 2026, ¥430M in tranche 2 later in 2026). Against FY2025 operating cash burn of ¥94.7M, the company has multiple years of runway. Total debt remains low (Finviz: Debt/Equity 0.06).

10. China beauty market: large, fragmented, accelerating in skincare

The Chinese beauty market exceeds ¥400B (~US$57B) and remains fragmented — even top players hold only single-digit market share, per CEO Huang's April 2025 Bloomberg China Show interview. Global personal care market expected to reach US$563B in 2026 growing at 5.24% CAGR; Asia-Pacific is the fastest-growing region (+7.49% CAGR through 2031), with skincare leading at 33.4% of category share. Source: mordorintelligence.com personal care report, yahoo finance Huang interview.

Recent News Timeline

No Results

What the Specialists Asked

Insider Spotlight

No Results

Key patterns:

Top 3 shareholders own 54% — minority shareholders have limited governance leverage, especially after the March 2026 dilutive structure.
Founder is doubling down economically via the convertible, but he is also the controlling counterparty — so the signal is muddied.
No public open-market insider buying captured in the searches; only one insider sale (Form 144, June 2025).

Industry Context

The global personal care market is structurally healthy but China-specific dynamics are mixed:

What this means for Yatsen:

Tailwind: Asia-Pacific is the largest and fastest-growing region; skincare is the highest-share product category at ~33%; premium products growing ~7%+ CAGR (faster than mass).
Headwind: China color cosmetics, where Perfect Diary built its franchise, has slowed materially (Yatsen's color cosmetics −9.1% in Q4 2025 vs. industry segment estimates above). Premium skincare is the right pivot, but Yatsen competes head-to-head with L'Oréal, Estée Lauder, Procter & Gamble brands at scale.
Structural: Even Chinese leaders hold only single-digit share (per CEO Huang) — the market is fragmented enough to support the "agile innovator" thesis, but it also means no incumbent has built a defensible moat through scale alone.

Yatsen's reported 2025 R&D-as-percentage-of-revenue and patent filings are management talking points but not independently verified in the search corpus. The substantive moat evidence remains the gross margin lift (73.7% Q4 2023 → 78.2% FY2025) — a trend that, if it continues, would mark a genuine premiumization rather than promotional discounting.